Press release -
Chr. Hansen acquires dairy ingredient supplier Hundsbichler
Through the acquisition of the assets of Austrian-based ingredient supplier Österreichische Laberzeugung Hundsbichler GmbH, Chr. Hansen will further expand its enzyme production and presence into the traditional segments of specialty cheeses. Hundsbichler products are widely recognized for high quality, and this acquisition will enable Chr. Hansen to offer cheesemakers a second-to-none product portfolio in the animal rennet space.
The acquisition confirms our commitment to the traditional segment of animal derived coagulants for our customers in the cheese industry. The market for traditional and specialty cheese continues to develop, and the acquisition of Hundsbichler ensures that Chr. Hansen’s Food Cultures & Enzymes business is well positioned to reap future growth opportunities. Sr. Commercial Development Mgr., Michael Fooken Jensen says:
“We’re very proud to take on Hundsbichler’s high quality products and will do our utmost to deliver the same exceptional service levels that the customers have been used to. Chr. Hansen was founded on the discovery of animal rennet in 1874 and therefore has a strong tradition and expertise in this field, and we therefore believe that we can create true value for our new customers.”
The acquired business
Hundsbichler, founded in 1947 and headquartered in Langkampfen, Austria, is among the leading suppliers of animal rennet to the cheese industry. Key products include the BioRen® brand ranging from mainstream products to more specialized items used for production of typical, traditional cheeses.
We see a strong fit between Chr. Hansen’s dairy business and Hundsbichler, which is expected to provide attractive opportunities for synergies within sales, including cross-selling, supply chain improvements and innovation. These synergies are expected to be achieved in the coming two years. The assets of Hundsbichler was acquired for an undisclosed amount and comprises customers, products, trademarks and production equipment. The acquisition will not impact the financial guidance of Chr. Hansen and will only have a minor impact on sales and earnings in 2018/19.”
For further information, please contact:
Camilla Lercke, Head of Media Relations
+45 53 39 23 84
Subjects
Categories
Chr. Hansen is a leading, global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. We develop and produce cultures, enzymes, probiotics and natural colors for a rich variety of foods, confectionery, beverages, dietary supplements and even animal feed and plant protection. Our product innovation is based on more than 30,000 microbial strains – we like to refer to them as ‘good bacteria’. Our solutions enable food manufacturers to produce more with less – while also reducing the use of chemicals and other synthetic additives – which make our products highly relevant in today’s world. We have been delivering value to our partners – and, ultimately, end consumers worldwide – for over 140 years. We are proud that more than one billion people consume products containing our natural ingredients every day. Revenue in the 2017/18 financial year was EUR 1,097 million. Chr. Hansen was founded in 1874 and is listed on Nasdaq Copenhagen.
